These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8288425)

  • 1. Benefits and costs of recombinant human erythropoietin for end-stage renal failure: a review. Benefits and costs of erythropoietin.
    McNamee P; van Doorslaer E; Segaar R
    Int J Technol Assess Health Care; 1993; 9(4):490-504. PubMed ID: 8288425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human erythropoietin: factors to consider in cost-benefit analysis.
    Sheingold SH; Churchill DN; Muirhead N; Laupacis A
    Am J Kidney Dis; 1991 Jan; 17(1):86-92. PubMed ID: 1898836
    [No Abstract]   [Full Text] [Related]  

  • 3. Anemia therapy: individual benefit and societal cost.
    Denton TA; Diamond GA; Matloff JM; Gray RJ
    Semin Oncol; 1994 Apr; 21(2 Suppl 3):29-35. PubMed ID: 8202723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recombinant human erythropoietin].
    Montloin A
    Rev Infirm; 1990 Dec; 40(19):33-4. PubMed ID: 2091207
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease.
    Stevens ME; Summerfield GP; Hall AA; Beck CA; Harding AJ; Cove-Smith JR; Paterson AD
    BMJ; 1992 Feb; 304(6825):474-7. PubMed ID: 1547417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada.
    Sheingold S; Churchill D; Muirhead N; Laupacis A; Labelle R; Goeree R
    Soc Sci Med; 1992 May; 34(9):983-91. PubMed ID: 1631611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries.
    Leese B; Hutton J; Maynard A
    Pharmacoeconomics; 1992 May; 1(5):346-56. PubMed ID: 10146999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease.
    Kimel M; Leidy NK; Mannix S; Dixon J
    Value Health; 2008; 11(1):57-75. PubMed ID: 18237361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversing the anemia of renal failure.
    Hatch FE
    Hosp Pract (Off Ed); 1990 Feb; 25(2A):25-34. PubMed ID: 2105980
    [No Abstract]   [Full Text] [Related]  

  • 10. Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.
    Whittington R; Barradell LB; Benfield P
    Pharmacoeconomics; 1993 Jan; 3(1):45-82. PubMed ID: 10146987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recombinant human erythropoietin].
    Frenken LA; Koene RA
    Ned Tijdschr Geneeskd; 1988 Mar; 132(10):432-4. PubMed ID: 3347279
    [No Abstract]   [Full Text] [Related]  

  • 12. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis.
    Naci H; de Lissovoy G; Hollenbeak C; Custer B; Hofmann A; McClellan W; Gitlin M
    J Med Econ; 2012; 15(2):293-304. PubMed ID: 22115328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human erythropoietin in end-stage renal disease.
    Bihl G
    S Afr Med J; 2002 Aug; 92(8):565. PubMed ID: 12244602
    [No Abstract]   [Full Text] [Related]  

  • 14. Anemia treatment in chronic renal insufficiency.
    Fishbane S
    Semin Nephrol; 2002 Nov; 22(6):474-8. PubMed ID: 12430091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant erythropoietin as treatment for the late hyporegenerative anemia of Rh hemolytic disease.
    Ohls RK; Wirkus PE; Christensen RD
    Pediatrics; 1992 Nov; 90(5):678-80. PubMed ID: 1408538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia.
    Papatheofanis FJ; McKenzie RS; Mody SH; Suruki RY; Piech CT
    Curr Med Res Opin; 2006 May; 22(5):837-42. PubMed ID: 16709305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-effectiveness analysis of anemia screening before erythropoietin in patients with end-stage renal disease.
    Hutchinson FN; Jones WJ
    Am J Kidney Dis; 1997 May; 29(5):651-7. PubMed ID: 9159297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant erythropoietin and blood transfusions in cancer chemotherapy-induced anemia.
    Griggs JJ; Blumberg N
    Anticancer Drugs; 1998 Nov; 9(10):925-32. PubMed ID: 9890704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the use of recombinant human erythropoietin in anaemia of prematurity cost-effective?
    Meyer MP; Haworth C; McNeill L
    S Afr Med J; 1996 Mar; 86(3):251-3. PubMed ID: 8658295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option.
    Cornes P; Coiffier B; Zambrowski JJ
    Curr Med Res Opin; 2007 Feb; 23(2):357-68. PubMed ID: 17288690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.